Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004
(1997; 72 pages) View the PDF document
Table of Contents
Close this folderExecutive summary
View the documentBackground
View the documentDrug financing issues
View the documentCost-sharing for drugs
View the documentMonitoring for equity and quality
View the documentConclusions and recommendations
View the documentWorkshop evaluation
Open this folder and view contents1. Introduction
Open this folder and view contents2. Country presentations on drug financing
Open this folder and view contents3. Korat provincial field visit
Open this folder and view contents4. Drug financing issues
Open this folder and view contents5. Country priorities for drug financing
Open this folder and view contents6. Priorities for work group action
Open this folder and view contents7. Conclusions and recommendations
View the documentAnnex A. Agenda
View the documentAnnex B. List of participants
View the documentAnnex C. List of documents
View the documentAnnex D. Message from Regional Director, WHO South-East Asia Region
Open this folder and view contentsAnnex E. Evaluation of the meeting. Priorities for the Working Group
 

Monitoring for equity and quality

User fee programmes can have positive effects, such as increasing access to essential drugs and improving rational use of drugs. But user fee programmes can also have negative effects, such as reduced access to treatment and reduced public expenditure for health. When embarking on a new user fee programme or when making significant changes in an existing programme, it is essential that the effects of the programme be carefully monitored. The following questions should always be asked in monitoring the cost-sharing programme:

• Revenue generation - Are cash and insurance revenues generated as expected from service volume?

• Revenue expenditure - Is the expenditure spent according to guidelines, 75% for the facility and 25% for public health care expenditure?

• Quality impact -Is quality of service improving?

• Equity effects - Are people being excluded from essential health services because of fees? Or are households worse off because of fees?

• Budget impact - Is fee revenue supplementing or substituting for central Treasury expenditures?

Experience from monitoring user fee programmes in Africa and Asia indicates that four types of monitoring methods should be used together: (1) field supervision, (2) routine reporting, (3) sentinel systems, and (4) special studies. Each type of monitoring provides different information and has different resource requirements.

Country priorities for drug financing

Participants from each country identified the following main concerns and/or problems as their priorities:

• To increase the health budget as well as the drug budget.

• Inadequate financial support for drugs from Government. How to reduce irrational drug use (financial mechanisms to improve use and reduce cost)?

• Lack of coordinated effort among all nongovernental organizations (NGOs), and the public sector.

to previous section to next section
 

Last updated: May 3, 2013